Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
25 Leser
Artikel bewerten:
(0)

Point of Care Diagnostic Testing World Markets, 2018 - Research and Markets

DUBLIN, April 20, 2016 /PRNewswire/ --

Research and Marketshas announced the addition of the"Point of Care Diagnostic Testing World Markets"report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO )

This report describes latest developments in the point of care testing market segment. It examines clinical instruments, devices and reagents and supplies as utilized in near-patient environments like hospital emergency rooms, critical care units, clinics and doctor's offices. The study defines the dollar volume of point of care sales and makes five year projections - both in the U.S. and worldwide - including Europe, Asia and Latin America.

Point of care testing (POCT) enables rapid diagnostic tests to be performed while the patient is at the point of care facility where results can be obtained immediately, rather than waiting hours or even days for outside lab results to arrive. Point of care testing covers: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, food pathogens screening, hemoglobin diagnostics, infectious disease testing and cholesterol screening.

It also examines in detail the point of care sector for 25 individual country markets. A detailed summary of all important instruments in each clinical market is provided with emphasis on newly introduced products. Moreover, parallel areas where rapid detection is important using hand-held devices such as rapid detection of food pathogens and infectious diseases (MRSA, herpes simplex, avian flu, West Nile virus and typhoid) are discussed. Growth moderators and developing trends in point of care applications, as well as technology platform innovations and connectivity questions are examined in detail.

The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the point of care market in the U.S. and worldwide. Each company is discussed in depth, with a section on its history, product lines, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included.

Key Topics Covered:

1. Overview

2. Overview of Diagnostic Testing Point of Care Markets

3. Summary Analysis of the Global POCT Market: Value, Growth Rates and Market Share

4. Analysis of the U.S. POCT Market: Value, Growth Rates and Market Share

5. Analysis of the European POCT Market: Value, Growth Rates and Market Shares

6. Analysis of the POCT Markets for Japan, China and India: Value, Growth Rates and Market Share

7. Analysis of the Rest of World (ROW) POCT Market: Value, Growth Rates and Market Share

8. Review of the Market Segments, Reagents and Equipment

9. POCT: Growth Regulators

10. Business Trends in the POC Sector

11. Technology Platform Innovations in POCT

12. Data Management and Connectivity

13. Corporate Profiles

14. POCT Sector Trends and Forecasts

15. New Entrants to the Point of Care Market

Companies Mentioned - Partial List

- A. Menarini Diagnostics
- ACON Laboratories, Inc.
- Artron Laboratories, Inc.
- BioFire Diagnostics, Inc.
- BioMedomics
- BioScan Screening Systems, Inc.
- Biocartis SA
- Biomerica, Inc.
- Biosensia Ltd.
- Calypte Biomedical Corporation
- Chembio Diagnostic, Inc.
- Exalenz Bioscience
- GenBio
- LifeSign, LLC
- MBio Diagnostics, Inc.
- MedMira Laboratories
- Medica Corporation
- Medix Biochemica
- Menssana Research, Inc.
- Metaara Medical Technologies, Inc.
- Micronics
- New Horizons Diagnostics
- Nova Biomedical
- One Step Detect Associates, LLC
- Response Biomedical Corp.
- Roche Diagnostics
- Savyon Diagnostics
- Seegene
- Sekisui Diagnostics, LLC
- Senseonics
- Shanghai Ruicare Medical Co., Ltd.
- Shenzhen Fitconn Technology Co., Ltd.
- Telcare
- Trinity Biotech Plc
- bioMérieux


For more information visithttp://www.researchandmarkets.com/research/654wtk/point_of_care

Media Contact:

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

© 2016 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.